Promacta
Payments companies reported to CMS as associated with Promacta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Promacta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Promacta
These are the largest totals companies reported as associated with Promacta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Andrea Ventola | Florham Park, NJ | Obstetrics & Gynecology (Nurse Practitioner) | $144,895.79 |
| Wendy Hein | Kansas City, KS | Pediatrics (Nurse Practitioner) | $144,152.74 |
| Keith Mccrae | Cleveland, OH | Hematology & Oncology | $3,200.00 |
| James Bussel | New York, NY | Pediatric Hematology-Oncology | $2,940.00 |
| Michael Tarantino | Peoria, IL | Pediatric Hematology-Oncology | $2,940.00 |
| Craig Kessler | Washington, DC | Hematology & Oncology | $2,400.00 |
| Bart Scott | Seattle, WA | Medical Oncology | $2,110.39 |
| Danielle Nance | Gilbert, AZ | Hematology (Internal Medicine) | $2,025.00 |
| Cindy Neunert | Augusta, GA | Pediatric Hematology-Oncology | $1,875.00 |
| Girish Kunapareddy | Terre Haute, IN | Internal Medicine | $1,634.48 |
Prescribed Promacta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.